Neuravi said today that it raised $21 million in a Series B round for its Embotrap minimally invasive thrombectomy device. “The intention of the funding round is to launch the device in Europe, to run the Arise program for the U.S., to attempt to bring the device for U.S. approval and to continue to develop further […]
Life Sciences Partners
Direct Flow Medical raises a $32 million in funding round | Medtech funding for the week of December 1, 2014
Xeltis raises $34m for regenerative heart valve tech
Xeltis said today that it closed an over-subscribed Series B round worth about $34 billion for the regenerative heart valve technology it’s developing.
